|
|
Article: Ranbaxy Receives FDA Approval to Market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets.
- Article from:
- PR Newswire
- Article date:
- September 24, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PRINCETON, N.J., Sept. 24 /PRNewswire/ -- Ranbaxy Pharmaceuticals, Inc. ("RPI"), a wholly-owned subsidiary of Ranbaxy Laboratories Limited ("RLL") of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets, 10 mg/240 mg (24-Hour Formulation). The Division of Bioequivalence has determined Ranbaxy's Loratadine and Pseudoephedrine Sulfate Extended Release Tablets, 10 mg/240 mg (24-Hour Formulation) to be bioequivalent to the listed drug, Claritin-D(R) 24-Hour Extended Release Tablets of Schering Corporation. Total sales of $64.5 ...